Hansa Biopharma AB (publ) announced that the Nomination Committee has been formed in accordance with the principles adopted by the Annual General Meeting (AGM) on June 30, 2022 and has the following composition: Natalie Berner representing Redmile Group; Jannis Kitsakis representing AP4; Arne Myhrman representing Thomas Olausson.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
46.44 SEK | -4.91% | +9.37% | +77.25% |
May. 31 | Hansa Biopharma Finalizes Patient Randomization for Use of Imlifidase inKidney Transplantation Trial | MT |
May. 31 | Hansa Biopharma Completes Randomization in Pivotal Phase 3 Us Confides Trial | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+77.25% | 313M | |
+22.51% | 46.93B | |
+37.63% | 39.08B | |
-8.03% | 38.48B | |
+29.16% | 31.01B | |
-13.75% | 26.14B | |
+10.74% | 25.88B | |
+37.72% | 12.53B | |
-6.96% | 11.36B | |
-12.41% | 10.65B |
- Stock Market
- Equities
- HNSA Stock
- News Hansa Biopharma AB
- Hansa Biopharma AB Announces Formation of Nomination Committee